Doneer nu
Alzheimercentrum Amsterdam

Publicaties 2011

Internationale wetenschappelijke publicaties:

  • Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging and Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:270-279.
  • Bateman RJ, Aisen PS, de Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C. Autosomal-dominant Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s disease. Alzheimers Res Ther 2011;3(1):1-13.
  • Brodaty H, Breteler MMB, Dekosky ST, Dorenlot P, Fratiglioni L, Hock C, Kenigsberg P-A, Scheltens P, de Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011;59:923-927.
  • Cardoso MJ, Clarkson MJ, Ridgway GR, Modat M, Fox NC, Ourselin S,and The Alzheimer’s Disease Neuroimaging Initiative. LoAd: A locally adaptive cortical segmentation algorithm. Neuroimage 2011;56:1386-1397.
  • Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Thompson PM, Reiman EM, Jack CR Jr, Fox NC, Jagust WJ, Harvey DJ, Beckett LA, Gamst A, Aisen PS, Petersen RC, Weiner MW, for the Alzheimer’s Disease Neuroimaging Initiative. Impact of apolipoprotein ɛ4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. Alzheimers Dement 2011;7:514-520.
  • Clarkson MJ, Cardoso MJ, Ridgway GR, Modat M, Leung KK, Rohrer JD, Fox NC, Ourselin S. A comparison of voxel and surface based cortical thickness estimation methods. Neuroimage 2011;57:856-865.
  • Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain 2011;134:335-344.
  • Echávarri C, Aalten P, Uylings HBM, Jacobs HIL, Visser PJ, Gronenschild EHBM, Verhey FRJ, Burgmans S. Atrophy in the parahippocampal gyrus as an early biomarker of Alzheimer’s disease. Brain Struct Funct 2011;215:265-271.
  • Elias-Sonnenschein LS, Viechtbauer W, Ramakers IHGB, Verhey FRJ, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.  J Neurol Neurosurg Psychiatry 2011;82:1149-1156.
  • van der Flier WM, Pijnenburg YAL Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer’s disease: the case of the missing APOE ε4 allele. Lancet Neurol 2011;10:280-288.
  • Feldman FH, Scheltens Ph, Dubois B, on behalf of the International Working Group for New Research Criteria for AD.  New lexicon and criteria for the diagnosis of Alzheimer’s disease – Authors’ reply. Lancet Neurol 2011;11:300-301.
  • Fonteijn HM, Clarkson MJ, Modat M, Barnes J, Lehmann M, Ourselin S, Fox NC, Alexander DC.  An event-based disease progression model and its application to familial Alzheimer’s disease. Inf Process Med Imaging 2011;22:748-759.
  • Fox NC, Ridgway GR, Schott JM.Algorithms, atrophy and Alzheimer’s disease. Cautionary tales for clinical trials. Neuroimage 2011;57:15-18.
  • Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo K, Black SE. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia from the sunnybrook dementia study. J Alzheimers Dis 2011;26:379-388.
  • Goos JDC, van der Flier WM, Knol DL, Pouwels PJW, Scheltens P, Barkhof F, Wattjes MP. Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. Stroke 2011;42:1894-1900.
  • Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, Geurts JJG. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry 2011;82:126-135.
  • Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, K B, Carrillo M, Fox NC, Frisoni GB, Isaac M, Lovestone S, Nordberg A, Prvulovic D, Sampaio C, Scheltens P, Weiner M, Winblad B, Coley N, Vellas B, for the Oxford Task Force Group. Biomarkers for Alzheimer’s disease therapeutic trials. Prog Neurobiol 2011;95:579-593.
  • van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YAL, van der Flier WM, Scheltens P. Tau and p-tau as CSF biomarkers in dementia: a meta-analysis. Clin Chem Lab Med 2011;49:353-366.
  • Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC,  et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 2011;43:429-436.
  • Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer’s disease. Alzheimers Dement 2011;7:474-485.
  • Jansen C, Parchi P, Jelles B, Gouw AA, Beunders G, van Spaendonk RML, van de Kamp JM, Lemstra AW, Capellari S, Rozemuller AJM. The first case of fatal familial insomnia (FFI) in the Netherlands: a patient from Egyptian descent with concurrent 4 repeat tau deposits.  Neuropathol Appl Neurobiol 2011;37:549-553.
  • Jokinen H, Gouw AA, Madureira S, Ylikoski R, van Straaten ECW, van der Flier WM, Barkhof F, Scheltens P, Fazekas F, Schmidt R, Verdelho A, Ferro JM, Pantoni L, Inzitari D, Erkinjuntti T, On behalf of the LADIS Study Group. Incident lacunes influence cognitive decline: The LADIS study. Neurology 2011;76:1872-1878.
  • de Jong-Hagelstein M, van de Sandt-Koenderman WME, Prins ND, Dippel DWJ, Koudstaal PJ, Visch-Brink EG. Efficacy of early cognitive-linguistic treatment and communicative treatment in aphasia after stroke: a randomised controlled trial (RATS-2). J Neurol Neurosurg Psychiatry 2011;82:399-404.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Effect of a medical food on body mass index and activities of daily living in patients with Alzheimer’s disease: secondary analyses from a randomized, controlled trial. J Nutr Health Aging 2011;15:672-676.
  • Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM, Twisk JWR, Swinkels SHN, Scheltens P. Efficacy of a medical food on cognition in Alzheimer’s disease: results from secondary analyses of a randomized, controlled trial. J Nutr Health Aging 2011;15:720-724.
  • Kester MI, Verwey NA, van Elk EJ, Blankenstein MA, Scheltens P, van der Flier WM. Progression from MCI to AD: Predictive value of CSF Abeta42 is modified by APOE genotype. Neurobiol Aging 2011;32:1372-1378.
  • Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ, for the Alzheimer’s Disease Neuroimaging Initiative. (waaronder o.a. Fox N.) Genome-wide association study of CSF biomarkers Aβ1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011;76:69-79.
  • Knight WD, Okello AA, Ryan NS, Turkheimer FE, Rodríguez Martinez de Llano S, Edison P, Douglas J, Fox NC, Brooks DJ, Rossor MN. Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain 2011;134:293-300.
  • Koedam ELGE, Lehmann M, van der Flier WM, Scheltens P, Pijnenburg YAL, Fox N, Barkhof F, Wattjes MP. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 2011;21:2618-2625.
  • Lashley T, Rohrer JD, Bandopadhyay R, Fry C, Ahmed Z, Isaacs AM, Brelstaff JH, Borroni B, Warren JD, Troakes C, King A, Al-Saraj S, Newcombe J, Quinn N, Ostergaard K, Schøder HD, Bojsen-Møller M, Braendgaard H, Fox NC, Rossor MN, Lees AJ, Holton JL, Revesz T. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain 2011;134:2548-2564.
  • Lehmann M, Barnes J, Ridgway GR, Wattam-Bell J, Warrington EK, Fox NC, Crutch SJ.  Basic visual function and cortical thickness patterns in posterior cortical atrophy. Cereb Cortex 2011;21:2122-2132.
  • Lehmann M, Crutch SJ, Ridgway GR, Ridha BH, Barnes J, Warrington EK, Rossor MN, Fox NC. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer’s disease. Neurobiol Aging 2011;32:1466-1476.
  • Leung KK, Barnes J, Modat M, Ridgway GR, Bartlett JW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. Neuroimage 2011;55:1091-1108.
  • McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carillo MC, Thies B, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup. Alzheimers Dement 2011;7:263-269.
  • Mahoney CJ, Rohrer JD, Goll JC, Fox NC, Rossor MN, Warren JD. Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. J Neurol Neurosurg Psychiatry 2011;82:1274-1278.
  • Maruta C, Guerreiro M, de Mendonça A, Hort J, Scheltens P. The use of neuropsychological tests across Europe: the need for a consensus in the use of assessment tools for dementia. Eur J Neurol 2011;18:279-286.
  • Norberg J, Graff C, Almkvist O, Ewers M, Frisoni GB, Frölich L, Hampel H, Jones RW, Kehoe PG, Lenoir H, Minthon L, Nobili F, Olde Rikkert M, Rigaud A-S, Scheltens P, Soininen H, Spiru L, Tsolaki M, Wahlund L-O, Vellas B, Wilcock G, Elias-Sonnenschein LS, Verhey FRJ, Visser PJ. Regional differences in effects of APOE ε4 on cognitive impairment in non-demented subjects. Dement Geriatr Cogn Disord 2011;32:135-142.
  • O’Brien J, Scheltens P. Clinical use of neuroimaging in dementia: an international perspective. Int Psychogeriatr 2011;23(suppl 2):S3-S5.
  • Ossenkoppele R, Tolboom N, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BNM.  Afbeelden van amyloïdplaques in de hersenen met PET. Ned Tijdschr Geneeskd 2011;155:A2981.
  • Ossenkoppele R, van Berckel BNM, Tolboom N, PijnenburgYA, Prins ND, Lemstra AW, Lammertsma AA, Scheltens Ph. Moleculaire beeldvorming bij de ziekte van Alzheimer. Tschr Neurol Neurochir 2011;112:201-208.
  • Ossenkoppele R, van Berckel BNM, Prins ND. Amyloid imaging in prodromal Alzheimer’s disease. Alzheimers Res Ther 2011;3(5):26.
  • Oudega ML, van Exel E, Wattjes MP, Comijs HC, Scheltens P, Barkhof F, Eikelenboom P, de Craen AJM, Beekman ATF, Stek ML. White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients.  J Clin Psychiatry 2011;72:104-112.
  • Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011;10:829-843.
  • van de Pol L, Gertz H-J, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011;8:465-469.
  • Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini ML, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain  2011;134:2456-2477.
  • Rohrer JD, Lashley T, Holton J, Revesz T, Urwin H, Isaacs AM, Fox NC, Rossor MN, Warren J. The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 2011;82:1405-1407.
  • Rohrer JD, Lashley T, Schott JM, Warren JE, Mead S, Isaacs AM, Beck J, Hardy J, de Silva R, Warrington E, Troakes C, Al-Sarraj S, King A, Borroni B, Clarkson MJ, Ourselin S, Holton JL, Fox NC, Revesz T, Rossor MN, Warren JD. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011;134:2565-2581.
  • Ryberg C, Rostrup E, Paulson OB, Barkhof F, Scheltens P, van Straaten ECW, van der Flier WM, Fazekas F, Schmidt R, Ferro JM, Baezner H, Erkinjuntti T, Jokinen H, Wahlund L-O, Poggesi A, Pantoni L, Inzitari D, Waldemar G, and on behalf of the LADIS study group. Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. J Neurol Sci 2011;307:100-105.
  • Scheltens P, Rockwood K. How golden is the gold standard of neuropathology in dementia? Alzheimers Dement 2011;7:486-489.
  • Scher AI, Xu Y, Korf ESC, Hartley SW, Witter MP, Scheltens P, White LR, Thompson PM, Toga AW, Valentino DJ, Launer LJ. Hippocampal morphometry in population-based incident Alzheimer’s disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011;82:373-377.
  • Scherder E, Eggermont L, Visscher C, Scheltens P, Swaab D. Understanding higher level gait disturbances in mild dementia in order to improve rehabilitation; ‘Last in – first out’. Neurosci Biobehav Rev 2011;35:699-714.
  • Schmidt R, Schmidt H, Haybaeck J, Loitfelder M, Weis S, Cavalieri M, Seiler S, Enzinger C, Ropele S, Erkinjuntti T, Pantoni L, Scheltens P, Fazekas F, Jellinger K. Heterogeneity in age-related white matter changes. Acta Neuropathol 2011;122:171-178.
  • Schott JM, Warren JD, Barkhof F, Rossor MN, Fox NC. Suspected early dementia. BMJ 2011;343:d5568:1-5.
  • Sikkes SAM, Knol DL, van den Berg MT, de Lange-de Klerk ESM, Scheltens P, Klein M, Pijnenburg YAL, Uitdehaag, BMJ. An informant questionnaire for detecting Alzheimer’s disease: are some items better than others? J Int Neuropsychol Soc 2011;17:674-681.
  • Sims R, Dwyer S, Harold D, Gerrish A, Hollingworth P, Chapman J, Jones N, Abraham R, Ivanov D, Pahwa JS, Moskvina V, Dowzell K, Thomas C, Stretton A, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuiness B, Todd S, Johnston JA, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Livingston G, Bass NJ, Gurling H, McQuillin A, Jones L, Holmans PA, O’Donovan M, Owen MJ, Williams J. No evidence that extended tracts of homozygosity are associated with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 2011;156:764-771.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cgnitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2011;31:1-6.
  • Sperling RA, Jack CR Jr, Black SE, Frosch MP, Greenberg SM, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Black RS, Brashear HR, Grundman M, Siemers ER, Feldman HH, Schindler RJ. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-385.
  • Tabrizi SJ, Scahill RI, Durr A, Roos RAC, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC, and the TRACK-HD investigators. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-421.
  • Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, Frisoni GB, Weiner M, Schneider L, Gauthier S, Gispen-de Wied CC, Hendrix S, Feldman H, Cedarbaum J, Petersen R, Siemers E, Andrieu S, Prvulovic D, Touchon J, Hampel H. Prevention trials in Alzheimer’s disease: An EU-US task force report. Prog Neurobiol 2011;95:594-600.
  • Verdelho A, Madureira S, Moleiro C, Santos CO, Ferro JM, Erkinjuntti T, Poggesi A, Pantoni L, Fazekas F, Scheltens P, Waldemar G, Wallin A, Inzitari D, and on behalf of the LADIS study(waaronder Scheltens P, van Straaten I, Gouw A, van der Flier W, Visser M). Self-perceived memory complaints predict progression to Alzheimer disease. The LADIS study. J Alzheimers Dis  2011;27:491-498.
  • van Vliet D, de Vugt ME, Bakker C, Koopmans RTCM, Pijnenburg YAL, Vernooij-Dassen MJFJ, Verhey FR. Caregivers’ perspectives on the pre-diagnostic period in early onset dementia: a long and winding road. Int Psychogeriatr 2011;23:1393-1404.
  • de Waal H, Stam CJ, Blankenstein MA, Pijnenburg YAL, Scheltens P, van der Flier WM. EEG abnormalities in early and late onset Alzheimer’s disease: understanding heterogeneity. J Neurol Neurosurg Psychiatry 2011;82:67-71.
  • de Wilde MC, Kamphuis PJGH, Sijben JWC, Scheltens P. Utility of imaging for nutritional intervention studies in Alzheimer’s disease. Eur J Pharmacol 2011;668(suppl.1):S59-S69.
  • Witlox J, Kalisvaart KJ, de Jonghe JFM, Verwey NA, van Stijn MFM, Houdijk APJ, Traast HS, Maclullich AMJ, van Gool WA, Eikelenboom P. Cerebrospinal fluid β-amyloid and tau are not associated with risk of delirium: a prospective cohort study in older adults with hip fracture. J Am Geriatr Soc 2011;59:1260-1267.
  • Dröes, R.M., Van Mierlo, L.D., Meiland, F.J.M., Van der Roest, H.G. Memory problems in dementia: Adaptation and copingstrategies, and psychosocial treatments. Expert Reviews Neurotherapeutics, 2011,11(12)1769-1782.
  • De Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. Advance directives for euthanasia in dementia: how are they dealt with in Dutch nursing homes? Experiences of physicians and relatives.Journal of the American Geriatrics Society 2011;59(6):989-96.
  • Jansen APD, Van Hout HPJ, Nijpels G, Rijmen F, Dröes RM, Pot AM, Schellevis F, Van Marwijk HWJ, Stalman W. Effectiveness of case management among older adults with early symptoms of dementia and their primary informal caregivers: a randomised clinical trial. International Journal of Nursing Studies 2011 Aug;48(8):933-43.
  • Meiland FJM, Jonker C, Dröes RM. Predictors of effective support in meeting centers for people with dementia and their carers,Nonpharmacological therapies in dementia2010; 1(3):251-270.
  • Monfort JC, Villemur V, Lezy AM, Baron-Laforet S, Dröes RM. From paedophilia to gerontophilia. Lancet 2011; Vol. 377, Jan 22, 300. Van Mierlo LD, Meiland FJM, Dröes RM. Dementelcoach: effect of telephone coaching on carers of community dwelling people with dementia. Int Psychogeriatr. 2011 Oct 14:1-11.

Boek(hoofdstukken) en vakpublicaties:

  • Barkhof F, Fox NC, Bastos-Leite AJ, Scheltens Ph. Neuroimaging in dementia. New York, Springer, 2011. 278 pp.
  • van Exel E, Eikelenboom P, Comijs HC, Kurniawan C, Frölich M, Smit JH, Stek ML, Scheltens P, Eefsting JE, Westendorp  RGJ.  Het immuunsysteem en de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:637-643.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P. Alzheimer’s disease. In: Gilhus NE, Barnes M, Brainin M (eds), European handbook of neurological management. Oxford, John Wiley-Blackwell Publishing, 2011:269-281.
  • Kerklaan BJ, Scheltens P, Schoonderwoerd GC, Killestein J, Rozemuller AJM, van der Knaap MS. ‘Adult polyglucosan body disease’: een weinig bekende maar herkenbare wittestofziekte. Tschr Neurol Neurochir 2011;112:25-31.
  • Vos SJB, Visser PJ, Verhey FRJ. De rol van liquormarkers bij de vroege diagnostiek van de ziekte van Alzheimer. Tijdschr Psychiatr 2011;53:647-653.
  • Dijk M van, Weert J van, Dröes RM. De Veder methode. Contact maken door middel van theater. Denkbeeld; Tijdschrift voor Psychogeriatrie, 23, 2011, 2-5.
  • Mierlo L, Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.

Dissertaties:

  • Kester, MI. Biomarkers for Alzheimer’s pathology; monitoring, predicting and understanding the disease.
    Vrije Universiteit Amsterdam 14 januari 2011
    promotoren: Ph Scheltens, MA Blankenstein, copromotor: WM van der Flier
  • Mulder SD. Amyloid associated proteins in Alzheimer’s disease.
    Vrije Universiteit Amsterdam 7 oktober 2011
    promotoren: MA Blankenstein. Ph Scheltens, copromotor: R Veerhuis
  • Sikkes SAM. Measuring IADL in dementia.
    Vrije Universiteit Amsterdam 14 oktober 2011.
    promotoren: Ph Scheltens, BMJ Uitdehaag, copromotoren: YAL Pijnenburg, ESM de Lange-de Klerk
  • Sluimer JD. Visualizing the shrinking brain: longitudinal MR studies in the spectrum of cognitive decline.
    Vrije Universiteit Amsterdam 28 april 2011.
    promotoren: F Barkhof, Ph Scheltens, copromotoren: WM van der Flier, H. Vrenken
  • Van der Roest HG. Care needs in dementia and digital interactive information provisioning.
    Vrije Universiteit Amsterdam 12 oktober 2009
    Promotoren: RM Dröes, C Jonker, copromotoren: FJ Meiland, P. Scheltens
Top
Volg ons via